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Background: Many systematic reviews and meta-analysis have indicated beneficial effects of adjunctive systemic 
antibiotics in periodontal therapy in specific situations. However, some essential issues such as the ideal time of 
their administration during periodontal therapy remain unanswered. This systematic review aimed to determine 
at which phase of periodontal treatment would adjunctive systemic antibiotics lead to the best clinical outcomes, 
during the active phase or in the reevaluation phase.
Material and Methods: Searches in the databases Medline, Scopus and Cochrane Library were conducted. The 
randomized clinical trials and retrospective cohort studies comparing the clinical benefits of adjunctive systemic 
antibiotic administration in the active phase of periodontal treatment versus their administration in the reevaluation 
phase were included. The primary outcomes assessed were differences in clinical changes in periodontal pocket 
depth and clinical attachment loss at all post-treatment phases. 
Results: Of the 6209 records identified, two randomized clinical trials and two retrospective cohort studies were 
eligible according to inclusion criteria. Two studies suggested there were greater clinical benefits when systemic 
antibiotics were prescribed during the active phase of periodontal therapy than in the reevaluation phase while two 
other studies showed no significant difference in clinical outcomes at 6 months between these two different timing 
of administration. 
Conclusions: The evidence available and evaluated in this systematic review is of heterogeneous quality and limi-
ted by the restricted number of studies and their dissimilarities in their study design and outcome reporting. Despite 
insufficient evidence to determine the ideal time to the adjunctive systemic antibiotic administration in the perio-
dontal therapy, it seems that prescription of systemic antibiotic at the active phase of periodontal therapy leads to 
better clinical outcomes.
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Introduction
The use of systemic antimicrobials as adjunct to mechani-
cal therapy has been indicated to potentiate the effects of 
non-surgical mechanical therapy in the cases of aggres-
sive periodontitis, severe and progressive periodontitis 
and in periodontitis associated with specific microbio-
logical profiles (1,2). Many reports, systematic reviews 
and meta-analysis have indicated beneficial effects of 
systemic antibiotics for patients with periodontal disea-
se in these clinical situations (1-5) with more pronoun-
ced effects in aggressive periodontitis than in chronic 
periodontitis and in initially deep sites compared with 
moderately deep sites (6). A wide range of systemic anti-
biotics has been tested in clinical studies demonstrating 
superiority of the combination of amoxicillin and metro-
nidazole over any other antibiotic agent in the treatment 
of different forms of periodontitis. However, there is cu-
rrently insufficient high quality evidence to recommend 
a specific agent, dose or duration (7). The optimal time 
of antimicrobial drug administration is another subject 
of discussion, as it remains controversial whether ad-
junctive systemic antibiotics should preferably be admi-
nistered during the initial non-surgical phase, or during 
the subsequent re-treatment at reevaluation. 
At present, there is very little data to guide the selection 
of the most appropriate timing of antibiotic adminis-
tration (8). Basing on some biological concepts, some 
studies recommend the use of systemic adjunctive anti-
biotic agents at the initial phase of treatment (9-11), as 
it was recommended in the consensus report of the sixth 
European Workshop on Periodontology (12). However, 
in light of the enhanced antibiotic resistance develop-
ment, other reports support that it would be more judi-
cious to reevaluate each patient’s response to non-surgi-
cal periodontal therapy before deciding to prescribe or 
not adjunctive systemic antibiotic therapy (6). 
Therefore, this systematic review aims to determine 
which is the optimal time of systemic antibiotic admi-
nistration as an adjunct to periodontal therapy, during 
the active non-surgical phase or the reevaluation phase.
Material and Methods
-Protocol and registration
This Systematic review was conducted according to 
the Preferred Reporting Items for Systematic Review 
and Meta-Analysis (PRISMA) statement (13) and re-
gistered at the International Prospective Register of 
Systematic Reviews (PROSPERO) under the number 
CRD42019123386. 
-Focused Question
The review was conducted to assess whether timing of 
systemic adjunctive antibiotics influenced the outcomes 
of periodontal therapy. Specifically, the purpose of this 
review is to answer the following question: “Would ad-
junctive systemic antibiotic administration in the active 
phase of periodontal therapy provides greater clinical 
benefits than in the reevaluation phase?”
-Eligibility Criteria
Studies were assessed for eligibility based on the fo-
llowing criteria:
1. Study type: randomized control trials (RCT), or con-
trolled clinical trials (CCT), and retrospective cohort 
studies (RCS) were eligible for inclusion. Case-control 
studies were excluded. A minimum follow-up period of 
two months was required, but no restrictions were placed 
on the type of setting, language or year of publication.
2. Participants: patients with clinically diagnosed perio-
dontitis were eligible for inclusion. Patients who didn’t 
require antibiotic prescription were excluded.
3. Intervention: clinical studies comparing at least two 
groups, one test (systemic antibiotic administered at the 
reevaluation phase of periodontal therapy) and one con-
trol (systemic antibiotic administered at the active phase 
of periodontal therapy) were eligible for inclusion. The 
studies administering systemic antibiotic without asso-
ciated mechanical debridement or using local antibiotics 
or antibiotics in sub-antimicrobial doses were excluded. 
4. Outcome variables were differences in clinical chan-
ges in Periodontal Pocket Depth (PPD) and Clinical 
Attachment Loss (CAL) at all post-treatment points be-
tween the test and control groups.
-Information Sources
An electronic search of Medline, Scopus and the Co-
chrane Library databases was performed on the 26th of 
October 2018 for eligible clinical studies. The reference 
lists of all included studies and relevant reviews were 
manually cross-referenced to complete data collection.
-Search Strategy
The following search strategy was used for the Medline 
database and adapted adequately for the Scopus and Co-
chrane Library searches:
≠1 (“periodontal diseases” OR periodontitis OR “chro-
nic periodontitis” OR “aggressive periodontitis” OR 
“periodontal infection”) AND (“anti-infective agents” 
OR “antibacterial agents” OR “antimicrobial” OR anti-
biotics) AND (tim* OR delay OR phase) NOT photod-
ynamic.
-Study Selection
The search results were downloaded into a Zotero li-
brary. After removing duplicates, the library was saved 
and two reviewers (LA and AB) screened titles and abs-
tracts for eligibility. Full text articles for all studies that 
appeared to meet the inclusion criteria or could not be 
excluded for sure were obtained. Each article was asses-
sed independently against the eligibility criteria by two 
reviewers (LA and AB) and reasons for exclusion were 
reported. Disagreements between reviewers were argued 
and resolved by discussion.
-Data Collection & Items
Two independent reviewers (LA and AB) collected Data 
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from each included article. The following items were 
recorded within each included study: sample characteris-
tics, length of the study, diagnosis, treatment performed 
in test groups and controls (including the protocol of sca-
ling and root planning (SRP) (full-mouth or by quadrant), 
the antibiotic molecule, it’s dose, timing, frequency and 
duration and follow-up. The comparison of primary and 
secondary outcomes between test and control groups with 
statistical significance were also recorded. 
-Assessment of Risk of bias 
Two independent review authors (LA and AB) assessed 
the methodological quality of each study. Discrepancies 
were resolved by discussion to reach a consensus. 
Assessment of Risk of bias in clinical trials included 
was performed in accordance with the Cochrane Han-
dbook for Systematic Reviews of Interventions (14). 
Studies were assessed on seven criteria constituting 
potential sources of bias: Sequence generation, Allo-
cation concealment, Blinding of participants and per-
sonnel, Blinding of outcome assessors, Incomplete out-
come data, Selective outcome reporting, Others bias. 
Each criterion was judged at low risk of bias(yes), high 
risk of bias (no) or unclearly determined (unclear). The 
risk of bias of each study was then assessed as: “Low 
risk of bias”: if “yes” is found in all domains; “High 
Risk of Bias”: if “no” is met in any of the domains and 
“Unclear Risk of Bias”: if “unclear” is recorded in any 
of the domains. 
Assessment of Risk of bias in retrospective cohort stu-
dies included was performed in accordance with the 
Newcastle-Ottawa quality assessment scale for cohort 
studies (15). This scale is a ‘star’ rating system compri-
sing three domains:  selection of study groups, compa-
rability of groups, and outcome of interest assessment. 
Each criterion fulfilled is awarded by a one star. 
A study can be given a maximum of one star for each 
numbered criteria within the Selection and Outcome 
categories. A maximum of two stars can be allocated 
for Comparability category. A maximum of nine stars 
can be given for each study. The following thresholds 
were used for converting the Newcastle-Ottawa scales 
to Agency for Healthcare Research and Quality (AHRQ) 
standards (good, fair and poor) (15):
• If 3 or 4 stars were allocated in selection domain AND 
one or 2 stars in comparability domain AND 2 or 3 stars 
in outcome/exposure domain, the RCS is considered of 
“good quality”.
• If 2 stars were allocated in selection domain AND one 
or 2 stars in comparability domain AND 2 or 3 stars in 
outcome/exposure domain, the RCS is considered of 
“fair quality”.
• If no or one star was allocated in selection domain OR 
no star in comparability domain or one star in outcome/




The search strategy identified 2609 records from Med-
line, Scopus And Cochrane Library. After reading the 
titles and abstracts, 2598 studies were excluded, and 11 
were selected. No article was identified in the manual 
search. After reading the full text of the 11 selected stu-
dies, 7 were excluded (10,16-21) and 4 of them met the 
inclusion criteria (22-25) (Fig. 1). A flowchart for the 
study selection process is presented in Figure 1.
-Study characteristics and heterogeneity
Of the 4 included studies, 2 randomized controlled trials 
(22,23) and 2 retrospective cohort studies (24,25) repor-
ted on 187 patients, which included 94 test subjects and 
93 controls. 
Two studies selected patients with generalized aggres-
sive periodontitis (22,24), one study with localized 
aggressive periodontitis(25), and one study included 
Aggregatibacter actinomycetemcomitans-associated mo-
derate to advanced periodontitis including both chronic 
and aggressive periodontitis and participants aged up to 
70 years (23). Smokers were not excluded from studies 
except for one study who was also restricted to an Afri-
can-American population (25).
Follow up times varied from 6 months to 15 months. 
However, not all studies reported 3 months results after 
initial therapy (22).
The mode of non-surgical treatment varied between full 
mouth instrumentation (22,23,25), or quadrant instru-
mentation in four visits within two weeks (24), and all 
participants of studies used 0.2% chlorhexidine mou-
thwashes after treatment during 10 to 15 days. 
The dose and duration of antibiotic regimens used in 
the 4 included studies also varied, as outlined in table 
1. Amoxicillin was administered in 375 and 500mg do-
ses, while metronidazole was administered in 250 and 
500mg doses. All doses were given three times daily, 
and the duration of antibiotic therapy ranged between 
7 and 10 days. 
A re-treatment was performed by all the studies in the re-
evaluation at 3 months after the initial phase (non-surgi-
cal treatment) except for one study in which the re-treat-
ment was performed at 6 months after initial therapy 
(22).
Different approaches to treat the persistent residual poc-
kets were tested at the re-evaluation phase consisting of 
a non-surgical re-treatment in all studies except for one 
study which performed both non-surgical and surgical 
re-treatment based on the values of the periodontal poc-
kets depths, bleeding on probing and furcation involve-
ment (23).
The primary outcomes studied were also heterogeneous 
between the included studies (PPD reduction at sites 
with initial PPD≥7mm (22), number of sites per patient 
with PPD>4mm and that bleed after probing (BOP+) 
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Fig. 1: Prisma flowchart of study selection process.
(23), reductions of full mouth Probing Depth (PD) and 
Relative Attachment Levels (RAL)(24), reductions in 
mean Clinical Attachment Level (CAL) (25).
A summary of the characteristics of the included studies 
is reported in Table 1, 1 cont..
-Results of Individual Studies:
In Griffith’s study (22), both treatments i.e. antibiotics 
initially and antibiotics at the re-treatment resulted in 
improvements of the mean PPD and LCAL(lifetime cli-
nical attachment level) at both 6 and 8 months. The di-
fference in mean PPD in deep pockets (≥7 mm) was sta-
tistically and clinically significant between the 2 groups, 
with a difference of 0.9mm (P<0.001) at 2 months, 
1.4mm (P<0.001) at 6 months and 0.9mm (P<0.003) at 
8 months in favor of the group who had antibiotic initia-
lly. Similar patterns were observed for LCAL with sta-
tistically significant differences, but with a lower great-
ness of difference. 
According to the study of Mombelli (23), the adminis-
tration of the amoxicillin plus metronidazole in the first 
or second phase resulted in similar long-term outcome. 
At 3 and 6 months after initial therapy, the mean num-
ber of sites with pocket depths PD >4 mm and BOP per 
patient was significantly lower than at baseline in both 
groups, with no significant difference between the two 
groups (P=0.18, P=0.61 respectively). However, admi-
nistrating adjunctive antibiotics in the first phase result in 
fewer patient requiring further therapy, a shorter treatment 
time and a lower mean number of surgical interventions.
In the retrospective study of Kaner (24), giving systemic 
antibiotics as an adjunct to SRP resulted in significant 
clinical improvements over 6 months in both group A 
(immediate antibiotics group) and group B (late antibio-
tics group). However, except for BOP, the changes in all 
clinical parameters over time were significantly different 
between the two groups. At 3 months after the initial 
therapy, the immediate administration of antibiotics re-
sulted in significantly greater reductions in PD and RAL 
(for full- mouth means and for initially deep sites) and in 
the proportion of sites with PD >6mm compared to SRP 
alone in the late antibiotics group. After 6 months, both 
groups showed comparable changes in full-mouth PD 
and RAL, BOP and pus, and the proportions of deep si-
tes (PD>6mm). However, the immediate antibiotic group 
obtained statistically significantly higher reductions in the 
mean PD (-4.09 mm) and RAL (-2.50 mm) in deep sites 
(with PD>6 mm) in comparison with the late antibiotic 
group (-2.80 mm and -1.41 mm, respectively) (P<0.05).
The study of Beliveau (25) showed that administration 
of an antibiotic protocol immediately following mecha-
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Authors, year Study type Study length Sample Disease Treatment 
Griffiths et al. 
2011 (23) 
RCT 8 months N=41 
16-35Y 
F : 28 
M :13 
S : 9 
GAgP FIRST PHASE 
(initial phase) 
 
Group A (n =20) 
FMRSD + ATB (AMOX 
500 mg + MTZ 500 mg t.i.d 
/ 7days) 
+ CHX/2 weeks 
Group B (n= 21) 




6 months after first phase 
Follow-up: 2 months 
Groupe A (n=19) 
FMRSD + CHX/2 weeks 
without placebo 
Group B (n= 19) 
FMRSD + ATB (AMOX 500 mg + 
MTZ 500 mg t.i.d /7days) + 
CHX/2 weeks 
     Clinical Outcome 
M2T1 M6T1 M8T2 
Differences in mean PPD reduction in pockets≥7mm 







% of sites with ≥2mm of PPD reduction M(IQ) 
GA : 29(24,44) 
GB : 21(11,33) 
P=0.029 
GA : 30 (21,47) 
GB : 21 (9-33) 
P= 0.021 
GA : 31(24,46) 
GB : 27 (19,39) 
P=0.179 
Differences in mean gain in LCAL in pockets³7mm (Estimate in 







Authors, year Study type Study length Sample Disease Treatment 






15 months N=80 
25-70 y 
F : 39 
M : 41 













Group A (n=40) 
SRP(a)+ ATB(AMOX 375 







Group B (n=40) 
SRP(a) + Placebo+ CHX/10days 
(a) Full mouth within 48h 
PHASE T2 
(surgical periodontal therapy) 
3 months after phase T1 
Follow-up: 12 months 
Group A (n= 38) 
• Open flap debridement of all 
teeth with residual PD³6mm 
and all furcation involved 
teeth with residual 
pockets³5mm 
• SRP to sites with residual 
PD between 4 and 5 mm 
• + Placebo+ CHX/10days 
Group B (n= 37) 
• Group A protocol 
• + ATB(AMOX 375 mg + 
MTZ 500mg t.i.d/7days) 
• +CHX/ 10days 
     Clinical Outcome 
BASELINE M3T1 M6T2 
Number of sites with PD >4mm and BOP per patient 
(M±SD) 
GA : 34.5±29.0 





GA : 2.8±5.2 
GB : 2.2±5.0 
P= 0.61 
Number of participants with persistence of sites with PD>4 
mm and BOP (%) 
 GA : 25 (64.1%) 
GB : 34 (89.5% 
P=0.01 
GA : 11 (29.7%) 
GB : 15 (42.9%) 
P= 0.33 
Table 1: Summary of the characteristics and findings of the included studies.
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Authors, Year Study design Length study Sample Disease Treatment 
Kaner et al. 
2007 (25) 







Group A (n=17) 
SRP(b) + immediate ATB (AMOX 500+MTZ250 every 8h/10 
days) 
Group B (n=17) 
SRP(b) (subgingival reinstrumentation at BOP positive sites with 
PD≥4mm and at all sites exhibiting PD≥5mm) +Late ATB 
(AMOX 500+MTZ250 every 8 h /10 days) after 3months 
 
(b) SRP by quadrant in 4 visits within 2 weeks 
     Clinical Outcome 
0-3 months 3-6months 0-6 months 
Reduction in proportion of sites with PD >6mm (%) 







GB: - 30 
P= 0.291 
Mean changes PD (sites with deep pockets PD>6mm) (95%CI) 
GA: -3.83 
(-4.16, -3.5) 






























Authors, Year Study design Length study Sample Disease Treatment 










LAgP ImA group (n=17) 
SRP (c) + ATB (AMOX 500+ MTZ 250 t.i.d/7 days) immediately 
after the initial mechanical therapy 
DelA group (n=15) 
SRP + ATB (AMOX 500+ MTZ 250 t.i.d/7 days) at 3 months 
post-initial mechanical therapy 
(c)  SRP by full mouth debridement 
     Clinical Outcome 
Baseline 3 months 6 months 











Number of residual sites with CAL >2 mm for diseased sites 




Im A:6.5±7.4 (d) 






Table 1 cont.: Summary of the characteristics and findings of the included studies.
RCT : randomized clinical trial ; RCS: retrospective cohort study; N : number ; F : female ; M : male ; S: smoker; CS: current smoker; Y: years; 
GAgP : generalized aggressive periodontitis, LAgP : localized aggressive periodontitis ; SCP : severe chronic periodontitis, CP : chronic peri-
odontitis; AP : aggressive periodontitis; Aa + : detection of Aggregatibacter actinomycetemcomitans in a pooled sample from the deepest pocket 
of each quadrant; SRP: scaling and root planning; FMRSD: full-mouth root surface debridement; ATB: antibiotic; AMOX: amoxicillin; MTZ: 
metronidazole; t.i.d: three times per day; CHX: 0.2% chlorhexidine; M3T1: Three months after SRP at T1 (initial phase); M6T2: Six months af-
ter T2(second phase treatment); ImA: immediate antibiotic; DelA: delayed antibiotic; PD: probing depth; PPD: periodontal pocket depth; CAL: 
clinical attachment level; RAL: relative attachment level; BOP: bleeding on probing; LCAL: life –time cumulative attachment loss; M(IQ): 
median and interquartile range; M±SD: Mean ± standard deviation; CI: Confidence-Interval; P: P-value; (d) P<0.05 from baseline by ANOVA 
with tuckey’s multiple comparisons; (e) P<0.05 between groups by umpaired T-test and Mann-Whitney test.
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nical therapy resulted in significant reductions in mean 
CAL at both 3 and 6 months post-initial therapy while a 
significant reduction was observed only at 6 months in 
the delayed antibiotic (DelA) group. 
In addition, the percentage of sites with a PD >4mm was 
reduced in both immediate antibiotic (ImA) and DelA 
groups six months post-therapy, although a statistically 
significant reduction in PD three months following treat-
ment was observed only in the ImA group (P<0.05). 
A decrease in the percentage of sites with CAL>2mm at 
both 3 and 6 months was also observed in the ImA group, 
while this decrease was observed only at 6 months in the 
DelA group. Therefore, the early administration of anti-
biotics seems to result in a more rapid amelioration and 
maintenance of the major clinical parameters.
A summary of the results of the included studies is re-























et al. 2011 
(23)
Yes Yes No (a) Yes Yes Yes Yes High Risk 
of Bias
Mombelli 
et al. 2015 
(24)
Yes Unclear(b) Yes Yes Yes Unclear(c) Unclear(d) Unclear 
Risk of Bias
Table 2: Assessment of risk of bias in randomized clinical trials (RCT) included in accordance with the Cochrane Handbook for Systematic 
Reviews of Interventions (14).
(a) subjects were no longer blinded to the treatment received ; (b) Insufficient information to permit judgment; (c) It’s unclear if the 40 patients in 
each group were included in intention-to-treat-analysis; (d) The repartition of aggressive and chronic periodontitis cases is unclear within group 
A and B.
“yes”: Low risk of bias
“No”: High risk of bias
“Unclear”: Unclear risk of bias
-Risk of Bias Within Individual Studies:
The quality of each included clinical trial was assessed 
using the revised risk of bias assessment tool from the 
Cochrane Collaboration’s handbook version 5.1.0 (14). 
Based on the seven criteria analyzed, the Griffith’s study 
was estimated of “high risk of bias” and the Mombelli’s 
study “unclear risk of bias”., as it is depicted in Table 2.
Even if classified at low risk of bias in six of the seven 
criteria analyzed, the Griffith’s study was estimated at 
high risk of bias because of the absence of blinding of the 
participants and personnel to the treatment received. The 
Mombelli’s study was classified as having unclear risk of 
bias based on the uncertainty around three sources of bias. 
The quality of each retrospective cohort study included 
was assessed in accordance with the Newcastle-Ottawa 
quality assessment scale for cohort studies criteria and 
depicted in Table 3. The 2 RCS included scored indi-
1. Selection Kaner et al. 2007 (25) Beliveau et al. 2012 (26)
1) Representativeness of the exposed cohort ¯ ¯
2) Selection of the non-exposed cohort ¯ ¯
3) Ascertainment of exposure ¯ ¯




1)Comparability of cohorts based on the design or analysis ¯ ¯
3. Outcome
1) Assessment of outcome 
2) Was follow-up long enough for outcomes to occur ¯ ¯
3) Adequacy of follow up of cohorts ¯ ¯
Assessment Good quality Good quality
Table 3: Assessment of risk of bias in retrospective cohort studies (RCS) included in accordance with the Newcastle-Ottawa quality assessment 
scale for cohort studies (15).
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vidually 8 stars (4, 2 and 2 stars in respectively “selec-
tion”, “comparability” and “outcome” domains) and 
were rated good quality.
Discussion
The results of this systematic review demonstrated that 
up until today, only 4 studies including 2 RCS (24,25) 
and 2 RCT (22,23) in the literature compared the clinical 
effects of systemic antibiotics administered at different 
phases of mechanical therapy. 
Among them, 2 studies including 1 RCT (22) of high 
risk of bias and 1 RCS (24) of good quality suggested 
there were greater clinical benefits when metronidazole 
and amoxicillin association was administered during the 
active phase of periodontal therapy than in the non-surgi-
cal re-treatment phase. Individuals treated with antibio-
tics together with SRP in the initial phase of treatment, 
showed greater reduction in PD and greater gain in CAL 
in deep pockets at all the time points than individuals 
treated lately with antibiotics 3 or 6 months after SRP. 
The 2 others studies including 1 RCT (23) of unclear risk 
of bias and 1 RCS (25) of good quality, included in this 
systematic review showed that giving antibiotics in the 
first or second phase have had no influence on the long 
term outcome. Six or 12 months after therapy, the mean 
number of sites with PD >4 mm and BOP per patient 
was significantly lower than at baseline in both groups, 
with no significant difference between the two groups. 
However, fewer patients treated with adjunctive antibio-
tics in the first phase needed further therapy (23,25), the 
treatment time in the second phase was shorter, and the 
mean number of surgical interventions was lower (23). 
Furthermore, the differential microbiologic outcomes of 
this latest RCT was reported more recently and showed 
that giving the antibiotics during the first or second pha-
se yielded similar microbiologic outcomes after 1 year 
although antibiotics in the first phase reduced bacterial 
counts quicker at 3 months (16). These findings were 
therefore in accordance with the clinical outcomes of 
this RCT (23).
It’s important to point out therefore that in all these 4 
studies (22-25), the immediate antibiotic usage at initial 
therapy provided beneficial clinical responses earlier in 
the treatment compared to the its later usage at reevalua-
tion phase, thereby reducing the need for further therapy, 
which is both surgical and non-surgical in the RCT of 
Mombelli (23).
It is also worth considering that these studies present 
some limitations. First, the Griffith’s study (22) was not 
initially designed to compare the effectiveness of the an-
tibiotic given in different phases of treatment. It was a 
follow-up study of a randomized controlled trial which 
was performed in a previous study (26) in order to assess 
the adjunctive clinical effect of the administration of 
systemic amoxicillin and metronidazole in the non-sur-
gical treatment of generalized aggressive periodontitis 
(GAP). 
Second, in this study, no placebo has been used in the 
second phase and the longitudinal evaluation time was 
short. The different follow-up times between immediate 
antibiotic group and delayed antibiotic group (6 mon-
ths from initial antibiotic versus 2 months respectively) 
would constitute an additional limitation.
Furthermore, the heterogeneity between studies regar-
ding the study design, the populations studied, the type of 
disease and severity, the  modalities of non-surgical the-
rapy (full mouth debridement or quadrant debridement), 
dosage and duration of antibiotherapy, the approaches of 
re-treatment (non-surgical exclusively or both non-sur-
gical and surgical treatment) and the primary and secon-
dary outcomes, makes terminating conclusions about the 
best time to prescribe adjunctive antibiotics in periodon-
tal therapy difficult even if it emerges through these stu-
dies an early benefit for antibiotic administration in the 
active phase of treatment.
The conclusion of this review is somewhat consistent 
with another previous systematic review that compared 
the clinical effectiveness of systemic antibiotics admi-
nistered in the active stage of periodontal treatment or 
after the healing phase (8). Only one study (22) was 
included in this review which did not allow authors to 
draw any clear conclusion. The present systematic re-
view has an added value from methodological point of 
view (PRISMA recommendations, information sources, 
assessment of risk of bias,..), leading to more included 
studies, recent and available evidence to address the re-
search question.
One double-blinded, three armed, placebo-controlled 
and bi-centric RCT was also designed to address the 
question of which is the best time for the administration 
of antibiotics in patients with severe periodontitis but it’s 
still an ongoing trial and its findings have not been pu-
blished yet (17).
Some biologic concepts support the use of antibiotics 
during the active phase of therapy in association with 
mechanical debridement (11). Indeed, early intake of an-
tibiotics could result in rapid and significantly reduce in 
keystone pathogens leading to a greater recolonization 
of the periodontal pockets by beneficial species (27,28). 
Furthermore, the degree of periodontal tissue  inflam-
mation during the active phase of therapy, may provide 
a higher antibiotic concentration and uptake in subgin-
gival space  (24).
Concerning the clinical benefits of early antibiotic ad-
ministration, it could reduce the need for subsequent 
non-surgical and surgical interventions because of a 
decreased number of residual pockets (29-33) which 
may represent an important benefit to patients in many 
terms. First, it may avoid the risk of hard tissue trau-
ma from repeated attempts of instrumentation in locally 
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unresponsive sites or sites with recurrent disease (34). 
Second, it may also avoid the risks, stress and financial 
costs associated with surgical procedures. Furthermore, 
the immediate antibiotic usage at initial therapy provi-
ded beneficial clinical responses earlier in the treatment 
compared to its later usage at reevaluation phase. This 
rapid suppression of the periodontal infection could 
avoid the higher risk of future disease progression and 
of the potential systemic health consequences (11).
On the other hand, delaying antibiotic therapy to the se-
cond surgical treatment phase may be supported by the 
fact that scaling and root planing alone can be enough to 
control disease progression in most cases of periodon-
titis. Furthermore, given the limitations of non-surgical 
mechanical debridement and the limited effects of anti-
biotics on intact biofilm, a pocket access surgery may be 
required to completely eliminate the subgingival biofilm 
and calculus and therefore potentiate the effectiveness of 
systemic antibiotic at re-treatment (35,36). 
However, even though these arguments seem to be bio-
logically plausible, the literature data do not support 
them (2).
Otherwise, the major benefit for the delay in prescribing 
the antibiotics at the reevaluation phase relates to the 
avoidance of the risks associated with the administration 
of antibiotics, such as the development of side effects and 
the emergence of ‘new’ antibiotic-resistant species (11). 
Nonetheless, no major side effects are likely to be asso-
ciated with the systemic administration of metronidazole 
and amoxicillin (26,29,31,37,38) and the potential risk 
of causing resistant strains against the antibiotics used 
in the periodontal therapy is a controversial issue in the 
current literature (39,40). It has been suggested that the 
increase in proportions of antibiotic resistant species in 
the subgingival biofilm seem to be rather the consequen-
ce of selection of organisms that were initially resistant 
to the antibiotic before antibiotic intake for periodon-
tal purposes (41-43). Data assessing the emergence of 
‘new’ antibiotic-resistant species are not available in the 
literature and conducting studies specifically designed to 
answer this question is very difficult (11). 
Otherwise, according to Mombelli (36),  the treatment of 
a periodontal infection, once in a punctual way, with two 
drugs with different antimicrobial action (Amoxicillin and 
Metronidazole), in a controlled situation following mecha-
nical debridement, contributes probably little to the pro-
blem of resistance to antibiotics compared to the effects of 
the frequent prescription of antibiotics by dentists or doc-
tors for other therapeutic and prophylactic purposes.
Therefore, in view of all these arguments, the recom-
mendation to prescribe antibiotics in the active phase or 
at reevaluation in the treatment of periodontal infection 
should adhere to the same therapeutic principle used for 
the treatment of any other infection in the body, that is: 
the risks have to be broadly counterbalanced by expec-
ted benefits to the patient (11). In this regard, the possible 
negative effects of antibiotics including the potential risk 
of emergence of ‘new’ antibiotic-resistant species have to 
be balanced against the risk of delaying antibiotic pres-
cription in terms of potential risk of systemic health con-
sequences of a persisting periodontal infection, and the 
inconvenience, discomfort and financial consequences of 
further surgical or no-surgical retreatment (36).
Consequently, in our opinion, it may be judicious in the 
light of the new classification of periodontal diseases 
(44), to prescribe antibiotic as part of initial therapy in 
cases of periodontitis grade C,  i.e. in cases where the-
re is a risk of a rapid progression or a negative impact 
on systemic health and post-pone their prescription in 
the other cases of periodontitis at the reevaluation pha-
se when mechanical debridement alone has not given 
successful results. However, our suggestion must be su-
pported by more appropriate randomized clinical studies 
specifically designed for this purpose.
In conclusion, this systematic review didn’t find a strong 
evidence to determine with certainty the ideal time for 
the adjunctive use of antibiotics. Some of included stu-
dies in this systematic review were of questionable qua-
lity of evidence. Furthermore, their heterogeneity makes 
comparison difficult and terminating conclusions even 
more. Despite this insufficient evidence, it seems that 
prescription of systemic antibiotic at the active phase of 
periodontal therapy leads to better clinical outcomes. 
In future, more appropriate and standardized randomi-
zed clinical trials with longer follow-up periods must be 
conducted and completed by microbiological and immu-
nological studies in order to evaluate the impact of ti-
ming of adjunctive antibiotic therapy on the outcome of 
periodontal therapy. Additional research into the phar-
macokinetics of antibiotics in periodontal tissues during 
the different phases of periodontal therapy is also requi-
red to get a complete picture of the problem addressed.
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